Zimmer Biomet (ZBH) came out with quarterly earnings of $1.74 per share, missing the Zacks Consensus Estimate of $1.75 per share. This compares to earnings of $1.65 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -0.57%. A quarter ago, it was expected that this orthopedic device maker would post earnings of $1.98 per share when it actually produced earnings of $2.01, delivering a surprise of 1.52%. Over the last four quarters ...

345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Exhibit 99.1 Media Investors Heather Zoumas-Lubeski David DeMartino (445) 248-0577 (646) 531-6115 heather.zoumaslubeski@zimmerbiomet.com david.demartino@zimmerbiomet.com Zach Weiner (908) 591-6955 zach.weiner@zimmerbiomet.com Zimmer Biomet Announces Third Quarter 2024 Financial Results • Third quarter net sales of $1.824 billion increased 4.0% and 4.1% on a constant currency 1 basis • Third quarter diluted earnings per share were $1.23; adjusted 1 dilute ...

In its upcoming report, Zimmer Biomet (ZBH) is predicted by Wall Street analysts to post quarterly earnings of $1.75 per share, reflecting an increase of 6.1% compared to the same period last year. Revenues are forecasted to be $1.8 billion, representing a year-over-year increase of 2.9%.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 0.6% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during ...

Core Insights - Zimmer Biomet Holdings, Inc. is set to launch the Z1 Femoral Hip System for total hip arthroplasty at the 2024 AAHKS annual meeting, showcasing its advanced hip portfolio and enabling technologies [1][4] Group 1: Product Launch and Features - The Z1 Femoral Hip System is a triple-taper femoral system designed to enhance stability and efficiency in total hip arthroplasty, complementing the G7 Acetabular System [1][2] - The Z1 System offers collared and collarless options for cementless applications and includes three distinct neck options to accommodate various patient anatomies [2] - The system is designed to minimize the instrument footprint, thereby reducing processing and sterilization burdens for surgical teams [2] Group 2: Clinical Feedback and Innovations - Initial user feedback from surgeons indicates that the Z1 System is intuitive and versatile, enhancing the surgical experience compared to earlier models [3] - Zimmer Biomet has expanded its hip portfolio through strategic acquisitions, including OrthoGrid Systems, which provides AI-powered surgical assistance applications [3] - The OrthoGrid Hip AI technology offers real-time intra-operative guidance for optimal surgical outcomes, further enhancing the capabilities of the Z1 System [3] Group 3: Upcoming Presentations and Studies - At the AAHKS meeting, Zimmer Biomet will present data from three clinical studies related to hip arthroplasty, focusing on metal ion levels, clinical outcomes, and quality of life correlations [4]

Zimmer Biomet (ZBH) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report, which is expected to be released on October 30, 2024, might help the stock move higher if these key numbers are better t ...

Zimmer Biomet Holdings, Inc. (ZBH) is scheduled to report third-quarter 2024 results on Oct. 30, before market open. In the last reported quarter, the company's earnings of $2.01 beat the Zacks Consensus Estimate by 1.5%. ZBH beat on earnings in each of the trailing four quarters, the average surprise being 2.84%. Find the latest EPS estimates and surprises on Zacks Earnings Calendar. ZBH's Q3 Estimates The Zacks Consensus Estimate for revenues is pegged at $1.81 billion, suggesting a 3.3% rise from the yea ...

Group 1 - Zimmer Biomet Holdings, Inc. will host its third quarter earnings conference call on October 30, 2024, at 8:30 a.m. ET, with a news release available at 6:30 a.m. ET on the same day [1] - The conference call can be accessed via Zimmer Biomet's Investor Relations website and will be available for replay after the call [1] - U.S. and Canada participants can join the call by dialing (888) 204-4368, while international callers should use +1 (323) 994-2093, both requiring conference ID 5103691 [2] Group 2 - Zimmer Biomet is recognized as a global leader in medical technology, focusing on maximizing mobility and improving health through innovative products and integrated digital and robotic technologies [3] - The company has over 90 years of experience and is committed to delivering high-quality solutions to patients and providers, emphasizing a culture of evolution and innovation [4] - Zimmer Biomet operates in over 25 countries and has sales in more than 100 countries, showcasing its extensive global reach [5]

Zimmer Biomet's (ZBH) strategic efforts to drive growth in the Knee business are anchored by four meaningful pillars. The stabilization of the global musculoskeletal market is encouraging for future growth. By expanding its portfolio to include upper and lower joints, the company is enhancing its presence in emerging markets. Meanwhile, a debt-burdened balance sheet and adverse currency movements remain concerns for ZBH's operations. In the past year, this Zacks Rank #3 (Hold) stock has dropped 2.7% in valu ...

Zimmer Biomet's (ZBH) strategic product launches and stabilizing market trends bolster our confidence in this stock. However, factors like macroeconomic uncertainties put pressure on the bottom line. The stock carries a Zacks Rank #3 (Hold). Zimmer Biomet has been witnessing strong market share gains within the reconstructive Knees and Hips businesses in key geographies despite macroeconomic challenges. According to the company, procedure growth continues successfully, aided by no meaningful impact from sta ...

Zimmer Biomet Holdings, Inc. (ZBH) recently announced the signing of a definitive agreement to acquire OrthoGrid Systems, Inc., a privately-held medical technology company focused on artificial intelligence (AI)- driven surgical guidance systems for total hip replacement. The acquisition comprises more than 40 patents, two additional orthopedic applications with FDA clearance, and Hip AI, OrthoGrid's AI-powered, fluoroscopy-based surgical support platform. This acquisition is set to expand Zimmer Biomet's h ...